Cell signalling: Growth factors and tyrosine kinase receptors

Clinical and Translational Oncology

Volumn 8, Issue 2, 2006, Pages 77-82

  Perona, Rosario ^a  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; VASCULOTROPIN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GROWTH PROMOTOR; LIGAND; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN; TUMOR PROTEIN; VASCULOTROPIN A;

ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; CELL MEMBRANE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; CONNECTIVE TISSUE; CYTOPLASM; ENZYME ACTIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAMMAL CELL; MITOGENESIS; PANCREAS CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; WOUND HEALING; DRUG ANTAGONISM; GENETICS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; PHYSIOLOGY; PROTO ONCOGENE; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; GENES, ERBB; GENES, ERBB-1; GENES, ERBB-2; GROWTH SUBSTANCES; HUMANS; LIGANDS; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; SOMATOMEDINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33646847329     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-006-0162-1     Document Type: Article

References (11)

1. Arribas J, Baselga J. Who will benefit from treatment against EGFR? Lancet Oncol. 2005;6(5):257-8.
2. Favoni RE, de Cupis A. The role of polypeptide growth factors in human carcinomas: New targets for a novel pharmacological approach. Pharmacol Rev. 2000;52(2): 179-206. Review.
3. Hofmann F, Garcia-Echeverría C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today. 2005;10(15):1041-7. Review.
4. Hui CH, Hughes TP. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia. Clin Adv Hematol Oncol. 2003;1(9):538-45, 559, Review.
5. Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-54. Review.
6. Izumi Y, Hirata M, Hasuwa H, et al. A metalloprotease-disintegrin, MDC9/ meltrin gamma/ADAM9 and PKCdelta are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor. EMBO J. 1998;17 (24):7260-72.
7. Janne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J Clin Oncol. 2005;23(14):3227-34. Review.
8. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: Implications for signal transduction therapy. Semin Cancer Biol. 2004;14(4):262-70. Review.
9. Nygren P, Sorbye H, Osterlund P, Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta Oncol. 2005;44(3):203-17. Review.
10. Tammela T, Enholm B, Alitalo K, Paavonen K. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005;65 (3):550-63.
11. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-8. Review.